Prepaid expenses and other current assets consist of the following (in thousands):



	June 30, 2018		December 31, 2017
Deposits	$	431	$	21,940
Other prepaid expenses and receivables	13,897		4,208
Prepaid insurance and property taxes	2,045		2,580
VAT/GST receivable	5,577		8,097
Deferred tax charge	1,912		1,326
Other	4,880		3,135
	$	28,742	$	41,286

Related-party receivables consist of the following (in thousands):



	June 30, 2018		December 31, 2017
Third-party receivables due from Pfizer	$	66,651	$	36,425
HIS business acquisition related	11,707		62,382
	$	78,358	$	98,807

Third-party receivables due from Pfizer relates to trade accounts receivable that has already been collected from customers by Pfizer on our behalf. HIS business acquisition related receivables include amounts due from Pfizer related to the manufacturing and supply agreements and amounts we prepaid to Pfizer for operational expenses under the transition services agreement.

Pfizer became a related party to us when we issued 3.2 million shares of our common stock as partial consideration for the acquisition of HIS. On February 3, 2017, we entered into a transitional services agreement and two Manufacturing and Supply Agreements ("MSAs") with Pfizer (see Note 19, Collaborative and Other Arrangements). During the three and six months ended June 30, 2018, the revenue for goods manufactured for Pfizer was $19.5 million and $37.6 million, respectively. During the three and six months ended June 30, 2017, the revenue for goods manufactured for Pfizer was $21.0 million and $35.7 million, respectively. For the three and six months ended June 30, 2018, the cost of product manufactured by Pfizer for us was $22.6 million and $39.8 million, respectively. For the three and six months ended June 30, 2017, the cost of product manufactured by Pfizer for us was $26.3 million and $38.8 million, respectively.